Pharmacokinetics of high‐dose methotrexate in infants treated for acute lymphoblastic leukemia

200926 citationsJournal Articlegreen Open Access

Authors

Gudmar Lönnerholm · Uppsala University Hospital

Maria Grazia Valsecchi · University of Milano-Bicocca

Paola De Lorenzo · University of Milano-Bicocca

Martin Schrappe · University of Lübeck

Liisa Hovi · University of Helsinki

Myriam Campbell · Hospital Roberto del Rio

Georg Mann ·

Abstract

Our data provide no support for a change in the dosing rules for MTX used in Interfant-99. However, in view of the poor treatment results for infants, one might consider increase in the dose for patients who reach plasma levels below median after the first MTX dose.

Topics & Keywords

Acute Lymphoblastic Leukemia research Childhood Cancer Survivors' Quality of Life Pharmaceutical studies and practices

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pediatric Blood & Cancer

Volume 52, Issue 5, pp. 596-601

DOI: 10.1002/pbc.21925

Field-Weighted Citation Impact: 2.19